VYNEHIGH SIGNALOPERATIONAL10-K

VYNE initiated a strategic review in August 2025 to evaluate strategic alternatives while implementing significant cost reductions, signaling potential sale or restructuring of the company.

The strategic review language indicates management is actively exploring options including potential sale or partnership, which could result in significant changes to the business structure or ownership. The dramatic increase in outstanding shares from 15.2M to 33.3M suggests substantial dilutive financing occurred during this period, likely to fund operations during the strategic review process.

Comparing 2026-02-27 vs 2025-03-06View on EDGAR →
FINANCIAL ANALYSIS

VYNE's financials show a company in active cost-cutting mode with SG&A expenses slashed by 70% and R&D reduced by 38%, resulting in 33% improvement in net losses despite a 55% decline in total assets. The 84% reduction in total liabilities and near-elimination of accounts receivable suggests settlement of obligations and reduced business activity. While the cost reductions successfully improved the loss profile, the 47% decline in stockholders' equity combined with the doubling of share count indicates significant shareholder dilution occurred to fund the business through its strategic review process.

FINANCIAL STATEMENT CHANGES
Accounts Receivable
Balance Sheet
-97.7%
$7.6M→$173K

Receivables declined — improved collection efficiency or conservative revenue recognition.

Total Liabilities
Balance Sheet
-83.8%
$14.8M→$2.4M

Liabilities reduced 83.8% — deleveraging improves balance sheet strength and financial flexibility.

Current Liabilities
Balance Sheet
-83.8%
$14.8M→$2.4M

Current liabilities reduced — improved short-term financial position and working capital health.

SG&A Expense
P&L
-69.9%
$54.5M→$16.4M

SG&A reduced 69.9% — improved cost efficiency or headcount reduction improving operating margins.

Total Assets
Balance Sheet
-54.9%
$66.9M→$30.2M

Total assets contracted 54.9% — asset sales, write-downs, or balance sheet optimization underway.

Current Assets
Balance Sheet
-53.4%
$64.4M→$30.0M

Current assets declined 53.4% — monitor working capital adequacy and short-term liquidity.

Stockholders Equity
Balance Sheet
-46.7%
$52.1M→$27.8M

Equity declined sharply — large losses, buybacks, or write-downs reducing book value significantly.

R&D Expense
P&L
-37.8%
$30.9M→$19.2M

R&D spending cut 37.8% — could signal cost discipline or concerning reduction in innovation investment.

Net Income
P&L
+33.5%
-$39.8M→-$26.5M

Net income grew 33.5% — bottom-line growth signals improving overall business health.

Operating Income
P&L
+31.8%
-$43.6M→-$29.7M

Operating leverage kicking in — revenue growth outpacing cost growth, a hallmark of scaling businesses.

LANGUAGE CHANGES
NEW — 2026-02-27
PRIOR — 2025-03-06
ADDED
As of February 12, 2026, there were 33,323,171 shares of the registrant's Common Stock, par value $0.0001 per share, outstanding.
COMPANY REFERENCES Throughout this Annual Report, "VYNE," the "Company," "we," "us" and "our" refer to VYNE Therapeutics Inc.
We initially focused our development efforts with these molecules on immune-mediated inflammatory diseases, which are not being targeted by current BET inhibitors in development.
In August 2025, we initiated a strategic review to evaluate a range of options to maximize stockholder value, including the assessment of our internal pipeline, financing opportunities and strategic alternatives.
As part of this process, we evaluated opportunities for repibresib and VYN202, including as part of broader strategic alternatives.
In conjunction, we implemented cost reductions to extend our cash runway.
Following the strategic review, we entered into an Agreement and Plan of Merger and Reorganization, dated as of December 17, 2025, which was amended on January 30, 2026 (as amended, the "Merger Agreement") with Yarrow Biosciences, Inc.
("Yarrow"), pursuant to which, among other matters, Yellow Merger Sub Corp., a direct, wholly owned subsidiary of ours ("Merger Sub"), will merge with and into Yarrow, with Yarrow surviving as a wholly owned subsidiary of VYNE and the surviving corporation of the merger (the "Merger").
In connection with the Merger, VYNE will change its name to Yarrow Bioscience, Inc.
VYNE following the Merger is referred to herein as the Combined Company.
REMOVED
As of February 27, 2025, there were 15,209,862 shares of the registrant's Common Stock, par value $0.0001 per share, outstanding.
COMPANY REFERENCES Throughout this Annual Report on Form 10-K, "VYNE," the "Company," "we," "us" and "our" refer to VYNE Therapeutics Inc.
These risks include, but are not limited to, the following: Our business is substantially dependent on the successful development of our BET inhibitor product candidates; We may encounter delays in enrolling patients and successfully completing clinical trials for our product candidates, and may be delayed in, or prevented from, commencing such trials due to factors that are largely beyond our control; Clinical drug development is very expensive, time-consuming and uncertain.
Through our access to this library of new BET inhibitors, which comprise our InhiBET portfolio, we plan to develop product candidates for a diverse set of therapeutic indications.
We have chosen to initially focus our development efforts with these molecules on immune-mediated inflammatory diseases, which are not being targeted by current BET inhibitors in development.
Our lead program is repibresib gel (also known as VYN201 ), a topically administered, small molecule pan-BD BET inhibitor designed as a soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways while providing low systemic exposure.
In preclinical testing, repibresib produced consistent reductions in pro-inflammatory and disease-related biomarkers and improvements in disease severity across a variety of inflammatory and fibrotic preclinical models.
In November 2022, we initiated a Phase 1 clinical trial evaluating a topical formulation of repibresib first in healthy volunteers (Phase 1a) and then in subjects (Phase 1b) with nonsegmental vitiligo (NSV), an immune-mediated condition that has a high unmet need and only one approved therapy.
In the first quarter of 2023, we announced positive preliminary safety and tolerability, including hematology data, and predicted pharmacokinetic results (minimal systemic exposures) from the Phase 1a portion of the trial .
We initiated the Phase 1b portion of the trial in NSV subjects in January 2023 and announced positive data from the Phase 1b trial in October 2023.
MORE OPERATIONAL SIGNALS
NVDAHIGHNVIDIA has repositioned itself from a "full-stack computing infrastructure compa...
2026-02-25
NVDAHIGHNVIDIA has repositioned itself from a "full-stack computing infrastructure compa...
2026-02-25
NOWHIGHServiceNow has fundamentally repositioned itself as an AI-first platform company...
2026-01-29
TSLAHIGHTesla has fundamentally repositioned itself from an electric vehicle company to ...
2026-01-29
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →